The Biosimilars Forum is launching a new biosimilars education initiative.

The Partnership for Biosimilars Education and Access will focus on raising awareness and encouraging access to biosimilars in the United States.  The Forum released two free educational guides that provide background, insights, FAQs, and resources on biosimilars as part of the new initiative.

“The introduction of biosimilars is anticipated to help drive lower cost burdens for the U.S. health care system. It will also help expand earlier, more consistent access to these important medicines for patients with cancer, anemia, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn’s and other inflammatory bowel diseases,” says Juliana Reed, president of the Biosimilars Forum, in a news release.

The U.S. Food and Drug Administration (FDA) approved the first biosimilar in 2015, and more than 50 biosimilars are in development in the U.S.

Organizations wishing to collaborate with the Biosimilars Forum on the Partnership for Biosimilars Education and Access initiative are encouraged to contact the Biosimilars Forum or reach out via Twitter @USbiosimilars.